ArticleLa Radiologia medica2022
Cost-effectiveness analysis of including contrast-enhanced ultrasound in management of pancreatic cystic neoplasms.
Article in La Radiologia medica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Economic evaluations of early detection strategies for pancreatic cancer: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Pooled it
- Large language models for analyzing contrast-enhanced ultrasound reports of pancreatic cystic lesions.Quantitative imaging in medicine and surgery · 2026Article
- Evaluation of cystic neoplasms using EUS, MRI, and CT scan and treatment strategy.Annals of medicine and surgery (2012) · 2026Review
- Imaging Assessment of Complex Renal Cysts: Comparative Value of Superb Microvascular Imaging and Contrast-Enhanced Ultrasound.Journal of personalized medicine · 2026Article
- Radiological Assessment After Pancreaticoduodenectomy for a Precision Approach to Managing Complications: A Narrative Review.Journal of personalized medicine · 2025Review
- Diagnostic Value of Contrast-Enhanced Ultrasound in Differentiating Malignant from Benign Small Renal Masses After CT/MRI.Journal of clinical medicine · 2024Article
- Basic Principles and Role of Endoscopic Ultrasound in Diagnosis and Differentiation of Pancreatic Cancer from Other Pancreatic Lesions: A Comprehensive Review of Endoscopic Ultrasound for Pancreatic Cancer.Journal of clinical medicine · 2024Review
- Quantitative ultrasound (QUS) in the evaluation of liver steatosis: data reliability in different respiratory phases and body positions.La Radiologia medica · 2024Article
- Tips and tricks for a correct interpretation of contrast-enhanced ultrasound.La Radiologia medica · 2024Review
- Cost-effectiveness of severe acute malnutrition treatment delivered by community health workers in the district of Mayahi, Niger.Human resources for health · 2024Article
- Review
- Abdominal compartment syndrome: what radiologist needs to know.La Radiologia medica · 2023Review
- Real-Time Ultrasound-Computed Tomography Fusion with Volume Navigation to Assess Pancreatic Cystic Lesions.Current oncology (Toronto, Ont.) · 2023Article
- Prognostic Assessment of Gastropancreatic Neuroendocrine Neoplasm: Prospects and Limits of Radiomics.Diagnostics (Basel, Switzerland) · 2023Review
- Recent Advances in Ultrasound Breast Imaging: From Industry to Clinical Practice.Diagnostics (Basel, Switzerland) · 2023Review
- Modern aspects of the management of pancreatic intraductal papillary mucinous neoplasms: a narrative review.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePancreatic cystic neoplasms (PCN) management consists of non-invasive imaging studies (CT, MRI), with a high resource burden. We aimed to determine the cost-effectiveness of including contrast-enhanced ultrasound (CEUS) in the management of PCN without risk features. MATERIALS AND
methodsBy using a decision-tree model in a hypothetical cohort of patients, we compared management strategy including CEUS with the latest Fukuoka consensus, European and Italian guidelines. Our strategy for BD-IPMN/MCN < 1 cm includes 1 CEUS annually. For those between 1 and 2 cm, it includes CEUS 4 times/year during the first year, then 3 times/year for 4 years and then annually. For those between 2 and 3 cm, it comprises MRI twice/year during the first one, then alternating 2 CEUS and 1 MRI yearly.
resultsCEUS surveillance is the dominant strategy in all scenarios. CEUS surveillance average cost is 1,984.72 €, mean QALY 11.79 and mean ICER 181.99 €. If willingness to pay is 30,000 €, 45% of patients undergone CEUS surveillance of BDIPMN/MCN < 1 cm would be within budget.
conclusionGuidelines strategies are very effective, but costs are relatively high from a policy perspective. CEUS surveillance may be a cost-effective strategy yielding a nearly high QALYs, an acceptable ICER, and a lower cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.